TY - JOUR
T1 - PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer
AU - Vanaja, Donkena Krishna
AU - Ballman, Karla V.
AU - Morlan, Bruce W.
AU - Cheville, John C.
AU - Neumann, Roxann M.
AU - Lieber, Michael M.
AU - Tindall, Donald J.
AU - Young, Charles Y.F.
PY - 2006/2/15
Y1 - 2006/2/15
N2 - Purpose: We analyzed the expression of genes to identify reliable molecular markers in the diagnosis and progression of prostate cancer. Experimental Design: Gene expression profiling was done using HG-U133 set microarrays in 32 prostate cancer and 8 benign tissues of patients with cancer. Expression levels of 11 genes were selected for quantitative real-time PCR evaluation in 52 prostate cancer and 20 benign tissues. Further, to assess transcriptional inactivation, we analyzed the promoter methylation of genes by quantitative methylation-specific PCR in 62 tumor and 36 benign tissues. Results: Our results showed a significant down-regulation in the mRNA expression levels of PRIMA1, TU3A, PDLIM4, FLJ14084, SVIL, SORBS1, C21orf63, and KIAA1210 and up-regulation of FABP5, SOX4, and MLP in prostate cancer tissues by TaqMan real-time PCR. Quantitative methylation-specific PCR of PDLIM4, SVIL, PRIMA1, GSTP1, and PTGS2 detected prostate carcinoma with a sensitivity of 94.7%, 75.4%, 47.4%, 89.5%, and 87.7%, and a specificity of 90.5%, 75%, 54.2%, 95.8%, and 90.2%, respectively. Using this panel of methylation markers in combination, we were able to distinguish between prostate cancer and adjacent benign tissues with sensitivities and specificities of about 90% to 100%. Our data provide evidence of transcriptional repression of the putative tumor suppressor gene PDLIM4 by hypermethylation. Conclusions: Our analysis revealed differential expression of eight down-regulated and three up-regulated genes, implicating their role in prostate cancer development and progression. We further showed that the hypermethylation of PDLIM4 gene could be used as a sensitive molecular tool in detection of prostate tumorigenesis.
AB - Purpose: We analyzed the expression of genes to identify reliable molecular markers in the diagnosis and progression of prostate cancer. Experimental Design: Gene expression profiling was done using HG-U133 set microarrays in 32 prostate cancer and 8 benign tissues of patients with cancer. Expression levels of 11 genes were selected for quantitative real-time PCR evaluation in 52 prostate cancer and 20 benign tissues. Further, to assess transcriptional inactivation, we analyzed the promoter methylation of genes by quantitative methylation-specific PCR in 62 tumor and 36 benign tissues. Results: Our results showed a significant down-regulation in the mRNA expression levels of PRIMA1, TU3A, PDLIM4, FLJ14084, SVIL, SORBS1, C21orf63, and KIAA1210 and up-regulation of FABP5, SOX4, and MLP in prostate cancer tissues by TaqMan real-time PCR. Quantitative methylation-specific PCR of PDLIM4, SVIL, PRIMA1, GSTP1, and PTGS2 detected prostate carcinoma with a sensitivity of 94.7%, 75.4%, 47.4%, 89.5%, and 87.7%, and a specificity of 90.5%, 75%, 54.2%, 95.8%, and 90.2%, respectively. Using this panel of methylation markers in combination, we were able to distinguish between prostate cancer and adjacent benign tissues with sensitivities and specificities of about 90% to 100%. Our data provide evidence of transcriptional repression of the putative tumor suppressor gene PDLIM4 by hypermethylation. Conclusions: Our analysis revealed differential expression of eight down-regulated and three up-regulated genes, implicating their role in prostate cancer development and progression. We further showed that the hypermethylation of PDLIM4 gene could be used as a sensitive molecular tool in detection of prostate tumorigenesis.
UR - http://www.scopus.com/inward/record.url?scp=33644768137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644768137&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-2072
DO - 10.1158/1078-0432.CCR-05-2072
M3 - Article
C2 - 16489065
AN - SCOPUS:33644768137
SN - 1078-0432
VL - 12
SP - 1128
EP - 1136
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -